Pharmacy

The path to bundled payment success can be daunting. Here’s three universal concepts that will promote success under the various CMS models.

Rise in use of outpatient care and professional services contributed to quicker growth in spending for the privately insured over previous years.

Retail clinics emerge as a way to satisfy the growing demand for healthcare created by the newly insured under the ACA, but contrary to expectations, they do not appear to be leading to meaningful reductions in low-acuity ED visits.

Understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients.

Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.

Study examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients.

Failure to report accurate data can result in significant penalties for Medicaid managed care plans.

Alcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.

Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.

As part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.

Consumers are demanding transparency in the prices of drugs. Here’s how they are getting it.

Do copay assistance program offer a long-term solution for patients? Experts weigh in.

The advantages of using an advanced clinical decision support system fall into four general “reducing” categories. Here they are.

It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.

MCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country.

Executives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs.

Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?

Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments.

Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.

Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.

A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.

Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.

Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.